Market Newsdesk

NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) — Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:

• INDUS Realty Trust, Inc. (NASDAQ:
  
  INDT
  
  ), relating to its proposed sale to affiliates of Centerbridge Partners, L.P. and GIC Real Estate, Inc. Under the terms of the agreement, INDT shareholders are expected to receive $67.00 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/indus-realty-trust-inc. It is free and there is no cost or obligation to you.
• Partners Bancorp. (NASDAQ:
  
  PTRS
  
  ), relating to its proposed sale to LINKBANCORP, Inc. Under the terms of the agreement, PTRS shareholders are expected to receive 1.15 shares of LINKBANCORP stock per share they own. Click here for more information: https://www.monteverdelaw.com/case/partners-bancorp. It is free and there is no cost or obligation to you.
• Radius Global Infrastructure, Inc. (NASDAQ:
  
  RADI
  
  ), relating to its proposed sale to EQT Active Core Infrastructure and Public Sector Pension Investment Board. Under the terms of the agreement, RADI shareholders are expected to receive $15.00 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/radius-global-infrastructure-inc. It is free and there is no cost or obligation to you.
• Ranger Oil Corp. (NASDAQ:
  
  ROCC
  
  ), relating to its proposed sale to Baytex Energy Corp. Under the terms of the agreement, ROCC shareholders are expected to receive 7.49 shares of Baytex and $13.31 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/ranger-oil-corp. It is free and there is no cost or obligation to you.

About Monteverde & Associates PC

We are a national class action securities and consumer litigation law firm that has recovered millions of dollars for shareholders and iscommitted to protecting investors and consumers from corporate wrongdoing. Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013 and 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2020 Top Rated Lawyer. Our firm’s recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, over the years the firm has recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases.

If you own common stock in any of the above listed companies and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2023 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guarantee a similar outcome with respect to any future matter.

 

2023 Revenue Outlook Raised

(All amounts in U.S. dollars. Per share information based on diluted shares outstanding unless otherwise noted.

TORONTO, April 26, 2023 (GLOBE NEWSWIRE) — Celestica Inc. (TSX: CLS) (NYSE: CLS), a leader in design, manufacturing, hardware platform and supply chain solutions for the world’s most innovative companies, today announced financial results for the quarter ended March 31, 2023 (Q1 2023)^†.

“Building on last year’s strong performance, Celestica is off to a solid start in 2023,” said Rob Mionis, President and CEO, Celestica. “Our first quarter revenue exceeded the mid-point of our guidance range and non-IFRS adjusted EPS* was at the high end of our guidance range.”

“We are encouraged by the strength and resiliency of our financial results given the challenging macro environment. We believe that we are well positioned for growth, with the ability to innovate and meet the evolving needs of our customers. As a result, we are pleased to raise our 2023 revenue outlook and tighten both our 2023 non-IFRS operating margin* and non-IFRS adjusted EPS* outlooks towards the high end of their ranges. We remain on track to achieve our long-term financial objectives.”

Q1 2023 Highlights

• Key measures:

• Revenue: $1.84 billion, increased 17% compared to $1.57 billion for the first quarter of 2022 (Q1 2022).
• Non-IFRS operating margin*: 5.2%, compared to 4.4% for Q1 2022.
• ATS segment revenue: increased 14% compared to Q1 2022; ATS segment margin was 4.4%, compared to 5.0% for Q1 2022.
• CCS segment revenue: increased 20% compared to Q1 2022; CCS segment margin was 5.8%, compared to 3.9% for Q1 2022.
• Adjusted EPS (non-IFRS)*: $0.47, compared to $0.39 for Q1 2022.
• Adjusted return on invested capital (ROIC) (non-IFRS)*: 17.9%, compared to 13.9% for Q1 2022.
• Adjusted free cash flow (non-IFRS)*: $9.2 million, compared to $0.5 million for Q1 2022.

• IFRS financial measures (directly comparable to non-IFRS measures above):

• Earnings from operations as a percentage of revenue: 3.2%, compared to 2.6% for Q1 2022.
• EPS: $0.20, compared to $0.17 for Q1 2022.
• Return on invested capital (IFRS ROIC): 11.2%, compared to 8.1% for Q1 2022.
• Cash provided by operations: $72.3 million, compared to $35.3 million for Q1 2022.
• Repurchased 0.8 million subordinate voting shares (SVS) for cancellation for $10.6 million under our normal course issuer bid.

† Celestica has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity & Cloud Solutions (CCS). Our ATS segment consists of our ATS end market and is comprised of our Aerospace and Defense (A&D), Industrial, HealthTech and Capital Equipment businesses. Our CCS segment consists of our Communications and Enterprise (servers and storage) end markets. Segment performance is evaluated based on segment revenue, segment income and segment margin (segment income as a percentage of segment revenue). See note 3 to our March 31, 2023 unaudited interim condensed consolidated financial statements (Q1 2023 Interim Financial Statements) for further detail.
* Non-International Financial Reporting Standards (IFRS) financial measures (including ratios based on non-IFRS financial measures) do not have any standardized meaning prescribed by IFRS and therefore may not be comparable to similar financial measures presented by other public companies that report under IFRS or U.S. generally accepted accounting principles (GAAP). See “Non-IFRS Supplementary Information” below for information on our rationale for the use of non-IFRS financial measures. See Schedule 1 for, among other items, non-IFRS financial measures included in this press release, their definitions, uses, and a reconciliation of historical non-IFRS financial measures to the most directly comparable IFRS financial measures. Schedule 1 also includes a description of: (i) modifications implemented during 2022 to: (x) the IFRS financial measures to which non-IFRS operating earnings and non-IFRS operating margin are reconciled; and (y) the IFRS financial measure on which the measure we refer to as IFRS ROIC is based; and (ii) a modification commencing in Q1 2023 to the calculation of specified non-IFRS financial measures to account for a newly-applicable exclusion related to our total return swap. Prior period reconciliations and calculations included herein reflect the current presentation. The most directly-comparable IFRS financial measures to non-IFRS operating margin, non-IFRS adjusted EPS, non-IFRS adjusted ROIC and non-IFRS adjusted free cash flow are earnings from operations as a percentage of revenue, EPS, IFRS ROIC, and cash provided by operations, respectively.

Second Quarter of 2023 (Q2 2023) Guidance

	Q2 2023 Guidance
Revenue (in billions)	$1.75 to $1.90
Non-IFRS operating margin*	5.2% at the mid-point of our revenue and non-IFRS adjusted EPS guidance ranges
Adjusted SG&A (non-IFRS)* (in millions)	$64 to $66
Adjusted EPS (non-IFRS)*	$0.44 to $0.50

For Q2 2023, we expect a negative $0.19 to $0.25 per share (pre-tax) aggregate impact on net earnings on an IFRS basis for employee stock-based compensation (SBC) expense, amortization of intangible assets (excluding computer software), and restructuring charges; and a non-IFRS adjusted effective tax rate* of approximately 21% (which does not account for foreign exchange impacts or unanticipated tax settlements).

2023 Outlook Update

Based on our strong performance in Q1 2023 and our current and expected levels of demand, our 2023 outlook currently includes:

• revenue of at least $7.6 billion (raised from our previous outlook of at least $7.5 billion);
• non-IFRS operating margin* of between 5.0% and 5.5% (tightened from our previous outlook of between 4.5% to 5.5%); and
• non-IFRS adjusted EPS* of between $2.00 and $2.05 (tightened from our previous outlook of between $1.95 and $2.05).

Achievement of our current 2023 revenue outlook and the mid-point of our current 2023 non-IFRS adjusted EPS* outlook would represent an at least 5% revenue growth rate and a 7% non-IFRS adjusted EPS* growth rate from 2022.

Although we have incorporated the anticipated impact of supply chain constraints into the foregoing financial guidance and outlook to the best of our ability, their adverse impact (in terms of duration and severity) cannot be estimated with certainly, and may be materially in excess of our expectations.

* See Schedule 1 for the definitions of these non-IFRS financial measures. We do not provide reconciliations for forward-looking non-IFRS financial measures, as we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing or amount of various events that have not yet occurred, are out of our control and/or cannot be reasonably predicted, and that would impact the most directly comparable forward-looking IFRS financial measure. For these same reasons, we are unable to address the probable significance of the unavailable information. Forward-looking non-IFRS financial measures may vary materially from the corresponding IFRS financial measures. See Schedule 1 for a description of a modification to the calculation of these non-IFRS financial measures commencing in Q1 2023 to account for a newly-applicable exclusion related to our total return swap.

Intention of Onex Corporation (Onex) to Convert our Multiple Voting Shares (MVS) into SVS

On March 14, 2023, a Schedule 13D/A filed by Gerald W. Schwartz disclosed that Onex intends to convert its MVS in Celestica then held into SVS on a one-for-one basis in approximately six months from such date. After a successful operational and financial transformation, we view this as the next logical step in our evolution.

Summary of Selected Q1 2023 Results

	Q1 2023 Actual		Q1 2023 Guidance (2)
Key measures:
Revenue (in billions)	$1.84		$1.725 to $1.875
Non-IFRS operating margin*	5.2%		5.0% at the mid-point of our revenue and non-IFRS adjusted EPS guidance ranges
Adjusted SG&A (non-IFRS)* (in millions)	$64.3		$56 to $58
Adjusted EPS (non-IFRS)*	$0.47		$0.41 to $0.47
Directly comparable IFRS financial measures:
Earnings from operations as a % of revenue	3.2%		N/A
SG&A (in millions)	$77.9		N/A
EPS(1)	$0.20		N/A

* See Schedule 1 for, among other things, the definitions of, and exclusions used to determine, these non-IFRS financial measures, a reconciliation of such non-IFRS financial measures to the most directly comparable IFRS financial measures for Q1 2023, and a description of modifications implemented during 2022 to the IFRS financial measures to which non-IFRS operating earnings and non-IFRS operating margin are reconciled. Schedule 1 also includes a description of a modification to the calculation of these non-IFRS financial measures commencing in Q1 2023 to account for a newly-applicable exclusion related to our total return swap.

⁽¹⁾ IFRS EPS of $0.20 for Q1 2023 included an aggregate charge of $0.29 (pre-tax) per share for employee SBC expense, amortization of intangible assets (excluding computer software), and restructuring charges. See the tables in Schedule 1 and note 8 to the Q1 2023 Interim Financial Statements for per-item charges. This aggregate charge slightly exceeded the high end of our Q1 2023 guidance range of between $0.22 to $0.28 per share for these items due to an unanticipated increase in employee SBC expense, driven by an increase in the estimated number of performance share units expected to vest in the first quarter of 2024.

IFRS EPS for Q1 2023 included a $0.04 per share negative impact attributable to restructuring charges and a $0.01 per share negative impact arising from taxable temporary differences associated with the anticipated repatriation of undistributed earnings from certain of our Chinese subsidiaries, offset by a $0.05 favorable tax impact attributable to the reversals of tax uncertainties in one of our Asian subsidiaries. See notes 8 and 9 to the Q1 2023 Interim Financial Statements.

IFRS EPS of $0.17 for Q1 2022 included a $0.04 per share negative impact attributable to other charges (consisting most significantly of a $0.02 per share negative impact attributable to restructuring charges and a $0.01 per share negative impact attributable to Transition Costs (defined in Schedule 1)), and as a result of supply chain constraints and COVID-19-related workforce expenses and constraints, a $0.03 per share negative impact attributable to estimated Constraint Costs (defined as both direct and indirect costs, including manufacturing inefficiencies related to lost revenue due to our inability to secure materials, idled labor costs, and incremental costs for labor, expedite fees and freight premiums, cleaning supplies, personal protective equipment, and/or IT-related services to support our work-from-home arrangements), all partially offset by a $0.04 favorable tax impact attributable to the reversal of tax uncertainties in one of our Asian subsidiaries. See notes 8 and 9 to the Q1 2023 Interim Financial Statements.

⁽²⁾ For Q1 2023, our revenue exceeded the mid-point of our guidance range, non-IFRS adjusted EPS was at the high end of our guidance range, and non-IFRS operating margin exceeded the mid-point of our revenue and non-IFRS adjusted EPS guidance ranges. Non-IFRS adjusted SG&A for Q1 2023 was higher than the high end of our guidance range due to the impact of foreign exchange. Our IFRS effective tax rate for Q1 2023 was 34%. Our non-IFRS adjusted effective tax rate for Q1 2023 was 22%, higher than our anticipated estimate of approximately 21%, mainly due to jurisdictional profit mix.

Q1


2023 Webcast and Annual Shareholders Meeting Webcast

Management will host its Q1 2023 results conference call on April 27, 2023 at 8:00 a.m. Eastern Daylight Time (EDT). The webcast can be accessed at www.celestica.com. Celestica’s 2023 Annual Meeting of Shareholders (Meeting) will be held on April 27, 2023 at 9:30 a.m. EDT. As previously announced, the Meeting will be held virtually via audio-only webcast at https://meetnow.global/MR6KD4X. Online access to the Meeting will begin at 9:00 a.m. EDT.

Non-IFRS Supplementary Information

In addition to disclosing detailed operating results in accordance with IFRS, Celestica provides supplementary non-IFRS financial measures to consider in evaluating the company’s operating performance. Management uses adjusted net earnings and other non-IFRS financial measures to assess operating performance and the effective use and allocation of resources; to provide more meaningful period-to-period comparisons of operating results; to enhance investors’ understanding of the core operating results of Celestica’s business; and to set management incentive targets. We believe investors use both IFRS and non-IFRS financial measures to assess management’s past, current and future decisions associated with our priorities and our allocation of capital, as well as to analyze how our business operates in, or responds to, swings in economic cycles or to other events that impact our core operations. See Schedule 1 below.

About Celestica

Celestica enables the world’s best brands. Through our recognized customer-centric approach, we partner with leading companies in Aerospace and Defense, Communications, Enterprise, HealthTech, Industrial, and Capital Equipment to deliver solutions for their most complex challenges. As a leader in design, manufacturing, hardware platform and supply chain solutions, Celestica brings global expertise and insight at every stage of product development – from the drawing board to full-scale production and after-market services. With talented teams across North America, Europe and Asia, we imagine, develop and deliver a better future with our customers. For more information on Celestica, visit www.celestica.com. Our securities filings can be accessed at www.sedar.com and www.sec.gov.

Cautionary Note Regarding Forward-looking Statements

This press release contains forward-looking statements, including, without limitation, those related to: our anticipated financial and/or operational results and outlook, including statements made, and guidance and outlook provided, under the headings “
Second
Quarter of 2023 (Q2 2023) Guidance” and “2023 Outlook Update”; our credit risk; our liquidity; anticipated charges and expenses, including restructuring charges; the potential impact of tax and litigation outcomes; mandatory prepayments under our credit facility; interest rates; and our expectations with respect to insurance recoveries for tangible losses in connection with a recent fire at our Batam facility in Indonesia (Batam Fire). Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “continues,” “project,” “target,” “outlook,” “goal,” “guidance”, “potential,” “possible,” “contemplate,” “seek,” or similar expressions, or may employ such future or conditional verbs as “may,” “might,” “will,” “could,” “should,” or “would,” or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. For forward looking statements attributable to Celestica, we claim the protection of the safe harbor for forward-looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995, where applicable, and for forward-looking information under applicable Canadian securities laws. This press release also contains forward-looking statements related to Onex’ intentions with respect to Celestica’s securities. All forward-looking statements herein attributable to Onex are derived from the Statement on Schedule 13D/A filed by Gerald W. Schwartz with the U.S. Securities and Exchange Commission on March 14, 2023. We are not aware of Onex’s material assumptions underlying such statements or what Onex believes to be the material risks of such statements ultimately proving to be incorrect. Accordingly, we do not assume any responsibility or liability for the verification, accuracy or completeness of such information nor for updating or withdrawing such information should circumstance change in the future. There can be no assurance that Onex will convert any or all of its holdings of MVS into SVS or sell any holdings of Celestica securities.

Forward-looking statements are provided to assist readers in understanding management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. Forward-looking statements are not guarantees of future performance and are subject to risks that could cause actual results to differ materially from those expressed or implied in such forward-looking statements, including, among others, risks related to: customer and segment concentration; challenges of replacing revenue from completed, lost or non-renewed programs or customer disengagements; managing our business during uncertain market, political and economic conditions, including among others, global inflation and/or recession, and geopolitical and other risks associated with our international operations, including military actions, protectionism and reactive countermeasures, economic or other sanctions or trade barriers, including in relation to the Russia/Ukraine conflict; managing changes in customer demand; our customers’ ability to compete and succeed using our products and services; delays in the delivery and availability of components, services and/or materials, as well as their costs and quality; our inventory levels and practices; the cyclical and volatile nature of our semiconductor business; changes in our mix of customers and/or the types of products or services we provide, including negative impacts of higher concentrations of lower margin programs; price, margin pressures, and other competitive factors and adverse market conditions affecting, and the highly competitive nature of, the electronic manufacturing services (EMS) and original design manufacturer (ODM) industries in general and our segments in particular (including the risk that anticipated market conditions do not materialize); challenges associated with new customers or programs, or the provision of new services; interest rate fluctuations; rising commodity, materials and component costs as well as rising labor costs and changing labor conditions; changes in U.S. policies or legislation; customer relationships with emerging companies; recruiting or retaining skilled talent; our ability to adequately protect intellectual property and confidential information; the variability of revenue and operating results; unanticipated disruptions to our cash flows; deterioration in financial markets or the macro-economic environment, including as a result of global inflation and/or recession; maintaining sufficient financial resources to fund currently anticipated financial actions and obligations and to pursue desirable business opportunities; the expansion or consolidation of our operations; the inability to maintain adequate utilization of our workforce; integrating and achieving the anticipated benefits from acquisitions and “operate-in-place” arrangements; execution and/or quality issues (including our ability to successfully resolve these challenges); non-performance by counterparties; negative impacts on our business resulting from any significant uses of cash, securities issuances, and/or additional increases in third-party indebtedness (including as a result of an inability to sell desired amounts under our uncommitted accounts receivable sales program or supplier financing programs); disruptions to our operations, or those of our customers, component suppliers and/or logistics partners, including as a result of events outside of our control (including those described in “External Factors that May Impact our Business” in Item 5 of our 2022 Annual Report on Form 20-F); defects or deficiencies in our products, services or designs; volatility in the commercial aerospace industry; compliance with customer-driven policies and standards, and third-party certification requirements; negative impacts on our business resulting from our third-party indebtedness; the scope, duration and impact of materials constraints; coronavirus disease 2019 (COVID-19) mutations or resurgences; declines in U.S. and other government budgets, changes in government spending or budgetary priorities, or delays in contract awards; failure of the U.S. federal government to manage its fiscal matters or to raise or further suspend the debt ceiling, and changes in the amount of U.S. federal debt; the military conflict between Russia and Ukraine; changes to our operating model; foreign currency volatility; our global operations and supply chain; competitive bid selection processes; our dependence on industries affected by rapid technological change; rapidly evolving and changing technologies, and changes in our customers’ business or outsourcing strategies; increasing taxes (including as a result of global tax reform), tax audits, and challenges of defending our tax positions; obtaining, renewing or meeting the conditions of tax incentives and credits; the management of our information technology systems, and the fact that while we have not been materially impacted by computer viruses, malware, ransomware, hacking incidents or outages, we have been (and may in the future be) the target of such events; the impact of our restructuring actions and/or productivity initiatives, including a failure to achieve anticipated benefits therefrom; the incurrence of future restructuring charges, impairment charges, other unrecovered write-downs of assets (including inventory) or operating losses; the inability to prevent or detect all errors or fraud; compliance with applicable laws and regulations; our pension and other benefit plan obligations; changes in accounting judgments, estimates and assumptions; our ability to maintain compliance with applicable credit facility covenants; the discontinuation of LIBOR; our entry into a total return swap agreement; our ability to refinance our indebtedness from time to time; our credit rating; the interest and actions of our controlling shareholder; our eligibility for foreign private issuer status; activist shareholders; current or future litigation, governmental actions, and/or changes in legislation or accounting standards; volatility in our SVS price; the impermissibility of SVS repurchases, or a determination not to repurchase SVS, under any normal course issuer bid (NCIB); potential unenforceability of judgments; negative publicity; the impact of climate change; and our ability to achieve our environmental, social and governance targets and goals, including with respect to climate change and greenhouse gas emissions reduction. The foregoing and other material risks and uncertainties are discussed in our public filings at www.sedar.com
 and www.sec.gov
, including in our most recent Management’s Discussion and Analysis of Financial Condition and Results of Operations, our 2022 Annual Report on Form 20-F filed with, and subsequent reports on Form 6-K furnished to, the U.S. Securities and Exchange Commission, and as applicable, the Canadian Securities Administrators. Risks also include that Onex does not convert its then-held Celestica MVS into SVS in approximately 6 months, or at all.

The forward-looking statements contained in this press release are based on various assumptions, many of which involve factors that are beyond our control. Our material assumptions include: continued growth in our end markets; growth in manufacturing outsourcing from customers in diversified markets; no significant unforeseen negative impacts to our operations (including from mutations or resurgences of COVID-19); no unforeseen materials price increases, margin pressures, or other competitive factors affecting the EMS or ODM industries in general or our segments in particular, as well as those related to the following: the scope and duration of materials constraints (i.e., that they do not materially worsen), and their impact on our sites, customers and suppliers; our ability to fully recover our tangible losses caused by the Batam Fire through insurance claims; fluctuation of production schedules from our customers in terms of volume and mix of products or services; the timing and execution of, and investments associated with, ramping new business; the success of our customers’ products; our ability to retain programs and customers; the stability of currency exchange rates; supplier performance and quality, pricing and terms; compliance by third parties with their contractual obligations; the costs and availability of components, materials, services, equipment, labor, energy and transportation; that our customers will retain liability for product/component tariffs and countermeasures; global tax legislation changes; our ability to keep pace with rapidly changing technological developments; the timing, execution and effect of restructuring actions; the successful resolution of quality issues that arise from time to time; the components of our leverage ratio (as defined in our credit facility); our ability to successfully diversify our customer base and develop new capabilities; the availability of capital resources for, and the permissibility under our credit facility of, repurchases of outstanding SVS under our current NCIB, and compliance with applicable laws and regulations pertaining to NCIBs; compliance with applicable credit facility covenants; anticipated demand levels across our businesses; the impact of anticipated market conditions on our businesses; that global inflation and/or recession will not have a material impact on our revenues or expenses; our ability to achieve the expected long-term benefits from our PCI Private Limited acquisition; and our maintenance of sufficient financial resources to fund currently anticipated financial actions and obligations and to pursue desirable business opportunities. Although management believes its assumptions to be reasonable under the current circumstances, they may prove to be inaccurate, which could cause actual results to differ materially (and adversely) from those that would have been achieved had such assumptions been accurate. Forward-looking statements speak only as of the date on which they are made, and we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

  
All forward-looking statements attributable to us are expressly qualified by these cautionary statements.

Schedule 1

Supplementary Non-IFRS Financial Measures

The non-IFRS financial measures (including ratios based on non-IFRS financial measures) included in this press release are: adjusted gross profit, adjusted gross margin (adjusted gross profit as a percentage of revenue), adjusted selling, general and administrative expenses (SG&A), adjusted SG&A as a percentage of revenue, non-IFRS operating earnings (or adjusted EBIAT), non-IFRS operating margin (non-IFRS operating earnings or adjusted EBIAT as a percentage of revenue), adjusted net earnings, adjusted EPS, adjusted return on invested capital (adjusted ROIC), adjusted free cash flow, adjusted tax expense and adjusted effective tax rate. Adjusted EBIAT, adjusted ROIC, adjusted free cash flow, adjusted tax expense and adjusted effective tax rate are further described in the tables below.

Prior to the second quarter of 2022 (Q2 2022), non-IFRS operating earnings (adjusted EBIAT) was reconciled to IFRS earnings before income taxes, and non-IFRS operating margin was reconciled to IFRS earnings before income taxes as a percentage of revenue, but commencing in Q2 2022, are reconciled to IFRS earnings from operations, and IFRS earnings from operations as a percentage of revenue, respectively (as the most directly comparable IFRS financial measures). This modification did not impact either resultant non-IFRS financial measure. Since non-IFRS adjusted ROIC is based on non-IFRS operating earnings, in comparing this measure to the most directly-comparable financial measure determined using IFRS measures (which we refer to as IFRS ROIC), commencing in the third quarter of 2022, our calculation of IFRS ROIC is based on IFRS earnings from operations (instead of IFRS earnings before income taxes). This modification did not impact the determination of non-IFRS adjusted ROIC. Prior period reconciliations and calculations included herein reflect the current presentation. In addition, prior to Q2 2022, non-IFRS adjusted free cash flow was referred to as non-IFRS free cash flow, but has been renamed. Its composition remains unchanged.

In the fourth quarter of 2022, we entered into a total return swap (TRS) agreement (TRS Agreement). Similar to employee stock-based compensation (SBC) expense, quarterly fair value adjustments of our TRS (TRS FVAs) are classified in cost of sales and SG&A expenses in our consolidated statement of operations. Commencing in Q1 2023, TRS FVAs are excluded in our determination of the following non-IFRS financial measures included herein: adjusted gross profit, adjusted gross margin, adjusted SG&A, adjusted SG&A as a percentage of revenue, non-IFRS operating earnings, non-IFRS operating margin, adjusted net earnings and adjusted EPS (for the reasons described below). TRS FVAs also impact the determination of our non-IFRS adjusted tax expense and non-IFRS adjusted effective tax rate, however, such impact was de minimis in Q1 2023.

In calculating our non-IFRS financial measures other than non-IFRS adjusted free cash flow, management excludes the following items (where indicated): employee SBC expense, TRS FVAs, amortization of intangible assets (excluding computer software), and Other Charges (Recoveries) (defined below), all net of the associated tax adjustments (quantified in the table below), and any non-core tax impacts (tax adjustments related to acquisitions, and certain other tax costs or recoveries related to restructuring actions or restructured sites). In calculating non-IFRS adjusted free cash flow, management excludes expenditures for property, plant and equipment (net of proceeds from the sale of certain surplus equipment and property), lease payments, and Finance Costs (defined below) paid (excluding any debt issuance costs and when applicable, credit facility waiver fees paid).

We believe the non-IFRS financial measures we present herein are useful to investors, as they enable investors to evaluate and compare our results from operations in a more consistent manner (by excluding specific items that we do not consider to be reflective of our core operations), to evaluate cash resources that we generate from our business each period, and to provide an analysis of operating results using the same measures our chief operating decision makers use to measure performance. In addition, management believes that the use of a non-IFRS adjusted tax expense and a non-IFRS adjusted effective tax rate provide improved insight into the tax effects of our core operations, and are useful to management and investors for historical comparisons and forecasting. These non-IFRS financial measures result largely from management’s determination that the facts and circumstances surrounding the excluded charges or recoveries are not indicative of our core operations.

Non-IFRS financial measures do not have any standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures presented by other companies that report under IFRS, or who report under U.S. GAAP and use non-GAAP financial measures to describe similar financial metrics. Non-IFRS financial measures are not measures of performance under IFRS and should not be considered in isolation or as a substitute for any IFRS financial measure.

The most significant limitation to management’s use of non-IFRS financial measures is that the charges or credits excluded from the non-IFRS financial measures are nonetheless recognized under IFRS and have an economic impact on us. Management compensates for these limitations primarily by issuing IFRS results to show a complete picture of our performance, and reconciling non-IFRS financial measures back to the most directly comparable financial measures determined under IFRS.

The economic substance of the exclusions described above (where applicable to the periods presented) and management’s rationale for excluding them from non-IFRS financial measures is provided below:

Employee SBC expense, which represents the estimated fair value of stock options, restricted share units and performance share units granted to employees, is excluded because grant activities vary significantly from quarter-to-quarter in both quantity and fair value. In addition, excluding this expense allows us to better compare core operating results with those of our competitors who also generally exclude employee SBC expense in assessing operating performance, who may have different granting patterns and types of equity awards, and who may use different valuation assumptions than we do.

TRS FVAs represent mark-to-market adjustments to our TRS, as the TRS is recorded at fair value at each quarter end. We exclude the impact of these non-cash fair value adjustments (both positive and negative), as they reflect fluctuations in the market price of our SVS from period to period, and not our ongoing operating performance. In addition, we believe that excluding these non-cash adjustments permits a better comparison of our core operating results to those of our competitors.

Amortization charges (excluding computer software) consist of non-cash charges against intangible assets that are impacted by the timing and magnitude of acquired businesses. Amortization of intangible assets varies among our competitors, and we believe that excluding these charges permits a better comparison of core operating results with those of our competitors who also generally exclude amortization charges in assessing operating performance.

Other Charges (Recoveries) consist of, when applicable: Restructuring Charges, net of recoveries (defined below); Transition Costs (Recoveries) (defined below); net Impairment charges (defined below); consulting, transaction and integration costs related to potential and completed acquisitions, and charges or releases related to the subsequent re-measurement of indemnification assets or the release of indemnification or other liabilities recorded in connection with acquisitions, when applicable; legal settlements (recoveries); specified credit facility-related charges; and post-employment benefit plan losses. We exclude these charges and recoveries, because we believe that they are not directly related to ongoing operating results and do not reflect expected future operating expenses after completion of these activities or incurrence of the relevant costs, net of recoveries. Our competitors may record similar charges at different times, and we believe these exclusions permit a better comparison of our core operating results with those of our competitors who also generally exclude these types of charges, net of recoveries, in assessing operating performance.

Restructuring Charges, net of recoveries, consist of costs relating to: employee severance, lease terminations, site closings and consolidations, accelerated depreciation of owned property and equipment which are no longer used and are available for sale and reductions in infrastructure.

Transition Costs consist of costs recorded in connection with: (i) the transfer of manufacturing lines from closed sites to other sites within our global network; and (ii) the sale of real properties unrelated to restructuring actions (Property Dispositions). Transition Costs consist of direct relocation and duplicate costs (such as rent expense, utility costs, depreciation charges, and personnel costs) incurred during the transition periods, as well as cease-use and other costs incurred in connection with idle or vacated portions of the relevant premises that we would not have incurred but for these relocations, transfers and dispositions. Transition Recoveries consist of any gains recorded in connection with Property Dispositions. We believe that excluding these costs and recoveries permits a better comparison of our core operating results from period-to-period, as these costs or recoveries do not reflect our ongoing operations once these specified events are complete.

Impairment charges, which consist of non-cash charges against goodwill, intangible assets, property, plant and equipment, and right-of-use (ROU) assets, result primarily when the carrying value of these assets exceeds their recoverable amount.

Non-core tax impacts are excluded, as we believe that these costs or recoveries do not reflect core operating performance and vary significantly among those of our competitors who also generally exclude these costs or recoveries in assessing operating performance.

The following table (which is unaudited) sets forth, for the periods indicated, the various non-IFRS financial measures discussed above, and a reconciliation of non-IFRS financial measures to the most directly comparable financial measures determined under IFRS (in millions, except percentages and per share amounts):

	Three months ended March 31
	2022						2023
				% of revenue						% of revenue
IFRS revenue	$	1,566.9					$	1,837.8
IFRS gross profit	$	132.5		8.5	%		$	164.0		8.9	%
Employee SBC expense		5.6						8.5
TRS FVAs		—						0.1
Non-IFRS adjusted gross profit	$	138.1		8.8	%		$	172.6		9.4	%
IFRS SG&A	$	65.7		4.2	%		$	77.9		4.2	%
Employee SBC expense		(9.0	)					(13.5	)
TRS FVAs		—						(0.1	)
Non-IFRS adjusted SG&A	$	56.7		3.6	%		$	64.3		3.5	%
IFRS earnings from operations	$	40.6		2.6	%		$	59.4		3.2	%
Employee SBC expense		14.6						22.0
TRS FVAs		—						0.2
Amortization of intangible assets (excluding computer software)		9.3						9.2
Other Charges		4.8						4.6
Non-IFRS operating earnings (adjusted EBIAT) (1)	$	69.3		4.4	%		$	95.4		5.2	%
IFRS net earnings	$	21.8		1.4	%		$	24.7		1.3	%
Employee SBC expense		14.6						22.0
TRS FVAs		—						0.2
Amortization of intangible assets (excluding computer software)		9.3						9.2
Other Charges		4.8						4.6
Adjustments for taxes(2)		(2.3	)					(3.5	)
Non-IFRS adjusted net earnings	$	48.2					$	57.2
Diluted EPS
Weighted average # of shares (in millions)		124.7						121.6
IFRS earnings per share	$	0.17					$	0.20
Non-IFRS adjusted earnings per share	$	0.39					$	0.47
# of shares outstanding at period end (in millions)		124.1						120.7
IFRS cash provided by operations	$	35.3					$	72.3
Purchase of property, plant and equipment, net of sales proceeds		(16.4	)					(33.1	)
Lease payments		(11.2	)					(11.3	)
Finance Costs paid (excluding debt issuance costs paid)		(7.2	)					(18.7	)
Non-IFRS adjusted free cash flow (3)	$	0.5					$	9.2
IFRS ROIC % (4)		8.1	%					11.2	%
Non-IFRS adjusted ROIC % (4)		13.9	%					17.9	%

(1)	Management uses non-IFRS operating earnings (adjusted EBIAT) as a measure to assess performance related to our core operations. Non-IFRS operating earnings is defined as earnings from operations before employee SBC expense, TRS FVAs (defined above), amortization of intangible assets (excluding computer software), and Other Charges (defined above). See note 8 to our Q1 2023 Interim Financial Statements for separate quantification and discussion of the components of Other Charges.
(2)	The adjustments for taxes, as applicable, represent the tax effects of our non-IFRS adjustments (see below).

The following table sets forth a reconciliation of our non-IFRS adjusted tax expense and our non-IFRS adjusted effective tax rate to our IFRS tax expense and IFRS effective tax rate, respectively, for the periods indicated, in each case determined by excluding the tax benefits or costs associated with the listed items (in millions, except percentages) from our IFRS tax expense for such periods:

	Three months ended March 31
	2022		Effective tax rate			2023		Effective tax rate
IFRS tax expense and IFRS effective tax rate	$	9.0	29	%		$	13.0	34	%
Tax costs (benefits) of the following items excluded from IFRS tax expense:
Employee SBC expense		1.5					2.3
Amortization of intangible assets (excluding computer software)		0.8					0.8
Other Charges		—					0.4
Non-IFRS adjusted tax expense and non-IFRS adjusted effective tax rate	$	11.3	19	%		$	16.5	22	%

(3)	Management uses non-IFRS adjusted free cash flow as a measure, in addition to IFRS cash provided by (used in) operations, to assess our operational cash flow performance. We believe non-IFRS adjusted free cash flow provides another level of transparency to our liquidity. Non-IFRS adjusted free cash flow is defined as cash provided by (used in) operations after the purchase of property, plant and equipment (net of proceeds from the sale of certain surplus equipment and property), lease payments, and Finance Costs (defined below) paid (excluding any debt issuance costs and when applicable, credit facility waiver fees paid). Finance Costs consist of interest expense and fees related to our credit facility (including debt issuance and related amortization costs), our interest rate swap agreements, our TRS Agreement, our accounts receivable sales program and customers’ supplier financing programs, and interest expense on our lease obligations, net of interest income earned. We do not consider debt issuance costs paid (nil and $0.8 million in Q1 2023 and Q1 2022, respectively) or such waiver fees (when applicable) to be part of our ongoing financing expenses. As a result, these costs are excluded from total Finance Costs paid in our determination of non-IFRS adjusted free cash flow. We believe that excluding Finance Costs paid (other than debt issuance costs and credit-agreement-related waiver fees paid) from cash provided by operations in the determination of non-IFRS adjusted free cash flow provides useful insight for assessing the performance of our core operations. Note, however, that non-IFRS adjusted free cash flow does not represent residual cash flow available to Celestica for discretionary expenditures.
(4)	Management uses non-IFRS adjusted ROIC as a measure to assess the effectiveness of the invested capital we use to build products or provide services to our customers, by quantifying how well we generate earnings relative to the capital we have invested in our business. Non-IFRS adjusted ROIC is calculated by dividing annualized non-IFRS adjusted EBIAT by average net invested capital for the period. Net invested capital (calculated in the table below) is derived from IFRS financial measures, and is defined as total assets less: cash, ROU assets, accounts payable, accrued and other current liabilities, provisions, and income taxes payable. We use a two-point average to calculate average net invested capital for the quarter. Average net invested capital for Q1 2023 is the average of net invested capital as at March 31, 2023 and December 31, 2022. A comparable financial measure to non-IFRS adjusted ROIC determined using IFRS measures would be calculated by dividing annualized IFRS earnings from operations by average net invested capital for the period.

The following table sets forth, for the periods indicated, our calculation of IFRS ROIC % and non-IFRS adjusted ROIC % (in millions, except IFRS ROIC % and non-IFRS adjusted ROIC %).

	Three months ended
	March 31
	2022				2023
IFRS earnings from operations	$	40.6			$	59.4
Multiplier to annualize earnings		4				4
Annualized IFRS earnings from operations	$	162.4			$	237.6
Average net invested capital for the period	$	2,000.7			$	2,127.1
IFRS ROIC %(1)		8.1	%			11.2	%
	Three months ended
	March 31
	2022				2023
Non-IFRS operating earnings (adjusted EBIAT)	$	69.3			$	95.4
Multiplier to annualize earnings		4				4
Annualized non-IFRS adjusted EBIAT	$	277.2			$	381.6
Average net invested capital for the period	$	2,000.7			$	2,127.1
Non-IFRS adjusted ROIC %(1)		13.9	%			17.9	%
	December 31 2022				March 31 2023
Net invested capital consists of:
Total assets	$	5,628.0			$	5,468.1
Less: cash		374.5				318.7
Less: ROU assets		138.8				133.1
Less: accounts payable, accrued and other current liabilities, provisions and income taxes payable		3,003.0				2,873.9
Net invested capital at period end(1)	$	2,111.7			$	2,142.4
	December 31 2021				March 31 2022
Net invested capital consists of:
Total assets	$	4,666.9			$	4,848.0
Less: cash		394.0				346.6
Less: ROU assets		113.8				109.8
Less: accounts payable, accrued and other current liabilities, provisions and income taxes payable		2,202.0				2,347.4
Net invested capital at period end(1)	$	1,957.1			$	2,044.2

⁽¹⁾  See footnote 4 on the previous page.

CELESTICA INC.
CONDENSED CONSOLIDATED BALANCE SHEET
(in millions of U.S. dollars)
(unaudited)
	Note	December 31  2022				March 31  2023
Assets
Current assets:
Cash and cash equivalents		$	374.5			$	318.7
Accounts receivable	4		1,393.5				1,260.1
Inventories	5&12		2,350.3				2,403.3
Income taxes receivable			5.9				5.3
Other current assets	12		202.8				188.5
Total current assets			4,327.0				4,175.9
Property, plant and equipment			371.5				376.1
Right-of-use assets			138.8				133.1
Goodwill			321.8				321.6
Intangible assets			346.5				336.6
Deferred income taxes			68.9				72.5
Other non-current assets			53.5				52.3
Total assets		$	5,628.0			$	5,468.1
Liabilities and Equity
Current liabilities:
Current portion of borrowings under credit facility and lease obligations	6	$	52.2			$	51.1
Accounts payable			1,440.8				1,338.7
Accrued and other current liabilities	5		1,462.2				1,426.6
Income taxes payable			82.1				88.8
Current portion of provisions			17.9				19.8
Total current liabilities			3,055.2				2,925.0
Long-term portion of borrowings under credit facility and lease obligations	6		733.9				724.1
Pension and non-pension post-employment benefit obligations			77.0				79.3
Provisions and other non-current liabilities			32.5				34.7
Deferred income taxes			51.7				49.5
Total liabilities			3,950.3				3,812.6
Equity:
Capital stock	7		1,714.9				1,699.5
Treasury stock	7		(18.5	)			(10.3	)
Contributed surplus			1,063.6				1,027.9
Deficit			(1,076.6	)			(1,051.9	)
Accumulated other comprehensive loss			(5.7	)			(9.7	)
Total equity			1,677.7				1,655.5
Total liabilities and equity		$	5,628.0			$	5,468.1

       Commitments and Contingencies (note 11).

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

CELESTICA INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(in millions of U.S. dollars, except per share amounts)
(unaudited)
		Three months ended
		March 31
	Note	2022				2023
Revenue	3	$	1,566.9			$	1,837.8
Cost of sales	5		1,434.4				1,673.8
Gross profit			132.5				164.0
Selling, general and administrative expenses			65.7				77.9
Research and development			11.4				12.1
Amortization of intangible assets			10.0				10.0
Other charges	8		4.8				4.6
Earnings from operations			40.6				59.4
Finance costs	6		9.8				21.7
Earnings before income taxes			30.8				37.7
Income tax expense (recovery)	9
Current			13.5				17.9
Deferred			(4.5	)			(4.9	)
			9.0				13.0
Net earnings for the period		$	21.8			$	24.7
Basic earnings per share		$	0.17			$	0.20
Diluted earnings per share		$	0.17			$	0.20
Shares used in computing per share amounts (in millions):
Basic			124.6				121.5
Diluted			124.7				121.6

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

CELESTICA INC.
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(in millions of U.S. dollars)
(unaudited)
	Three months ended
	March 31
	2022				2023
Net earnings for the period	$	21.8			$	24.7
Other comprehensive income (loss), net of tax:
Items that may be reclassified to net earnings:
Currency translation differences for foreign operations		(2.8	)			(1.5	)
Changes from currency forward derivative hedges		3.0				1.1
Changes from interest rate swap derivative hedges		10.5				(3.6	)
Total comprehensive income for the period	$	32.5			$	20.7

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

CELESTICA INC.
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
(in millions of U.S. dollars)
(unaudited)
	Note	Capital stock (note  7 )				Treasury stock (note  7 )				Contributed surplus				Deficit				Accumulated other comprehensive loss (a)				Total equity
Balance — January 1, 2022		$	1,764.5			$	(48.9	)		$	1,029.8			$	(1,255.6	)		$	(26.8	)		$	1,463.0
Capital transactions:	7
Issuance of capital stock			0.2				—				(0.1	)			—				—				0.1
Repurchase of capital stock for cancellation(b)			(10.8	)			—				10.5				—				—				(0.3	)
Purchase of treasury stock for stock-based compensation (SBC) plans(c)			—				(1.0	)			—				—				—				(1.0	)
Equity-settled SBC			—				30.9				(15.8	)			—				—				15.1
Total comprehensive income (loss):
Net earnings for the period			—				—				—				21.8				—				21.8
Other comprehensive income (loss), net of tax:
Currency translation differences for foreign operations			—				—				—				—				(2.8	)			(2.8	)
Changes from currency forward derivative hedges			—				—				—				—				3.0				3.0
Changes from interest rate swap derivative hedges			—				—				—				—				10.5				10.5
Balance — March 31, 2022		$	1,753.9			$	(19.0	)		$	1,024.4			$	(1,233.8	)		$	(16.1	)		$	1,509.4
Balance — January 1, 2023		$	1,714.9			$	(18.5	)		$	1,063.6			$	(1,076.6	)		$	(5.7	)		$	1,677.7
Capital transactions:	7
Issuance of capital stock			0.1				—				(0.1	)			—				—				—
Repurchase of capital stock for cancellation(d)			(15.5	)			1.8				(1.9	)			—				—				(15.6	)
SBC cash settlement	7		—				—				(49.8	)			—				—				(49.8	)
Equity-settled SBC			—				6.4				16.1				—				—				22.5
Total comprehensive income (loss):
Net earnings for the period			—				—				—				24.7				—				24.7
Other comprehensive income (loss), net of tax:
Currency translation differences for foreign operations			—				—				—				—				(1.5	)			(1.5	)
Changes from currency forward derivative hedges			—				—				—				—				1.1				1.1
Changes from interest rate swap derivative hedges			—				—				—				—				(3.6	)			(3.6	)
Balance — March 31, 2023		$	1,699.5			$	(10.3	)		$	1,027.9			$	(1,051.9	)		$	(9.7	)		$	1,655.5

(a)	Accumulated other comprehensive loss is net of tax.
(b)	Consists of $7.8 paid to repurchase subordinate voting shares (SVS) for cancellation under our normal course issuer bid during the first quarter of 2022, substantially offset by the reversal of $7.5 accrued as of December 31, 2021 for the estimated contractual maximum number of permitted SVS repurchases (Contractual Maximum Quantity) under an automatic share purchase plan (ASPP) executed in December 2021 for such purpose (see note 7).
(c)	Consists of $34.8 paid to repurchase SVS for delivery obligations under our SBC plans during the first quarter of 2022, substantially offset by the reversal of $33.8 accrued as of December 31, 2021 for the estimated Contractual Maximum Quantity under a separate ASPP executed in December 2021 for such purpose (see note 7).
(d)	Consists of $10.6 paid to repurchase SVS for cancellation during the first quarter of 2023 and $5.0 accrued as of March 31, 2023 for the contractual maximum spend for SVS repurchases for cancellation under an ASPP executed in February 2023 for such purpose (see note 7).

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

CELESTICA INC.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(in millions of U.S. dollars)

(unaudited)

		Three months ended
		March 31
	Note	2022				2023
Cash provided by (used in):
Operating activities:
Net earnings for the period		$	21.8			$	24.7
Adjustments to net earnings for items not affecting cash:
Depreciation and amortization			35.9				38.3
Employee SBC expense	7		14.6				22.0
Total return swap fair value adjustments			—				0.2
Other charges	8		0.3				—
Finance costs			9.8				21.7
Income tax expense			9.0				13.0
Other			0.7				3.3
Changes in non-cash working capital items:
Accounts receivable			16.9				133.5
Inventories			(237.8	)			(53.0	)
Other current assets			(10.5	)			8.6
Accounts payable, accrued and other current liabilities and provisions			183.8				(129.2	)
Non-cash working capital changes			(47.6	)			(40.1	)
Net income tax paid			(9.2	)			(10.8	)
Net cash provided by operating activities			35.3				72.3
Investing activities:
Purchase of computer software and property, plant and equipment			(16.4	)			(33.1	)
Net cash used in investing activities			(16.4	)			(33.1	)
Financing activities:
Repayments under term loans	6		(4.6	)			(4.6	)
Lease payments			(11.2	)			(11.3	)
Issuance of capital stock			0.1				—
Repurchase of capital stock for cancellation	7		(7.8	)			(10.6	)
Purchase of treasury stock for stock-based plans	7		(34.8	)			—
SBC cash settlement	7		—				(49.8	)
Finance costs paid(a)	6		(8.0	)			(18.7	)
Net cash used in financing activities			(66.3	)			(95.0	)
Net decrease in cash and cash equivalents			(47.4	)			(55.8	)
Cash and cash equivalents, beginning of period			394.0				374.5
Cash and cash equivalents, end of period		$	346.6			$	318.7

(a)   Finance costs paid include debt issuance costs paid of nil and $0.8 in Q1 2023 and Q1 2022, respectively.

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

CELESTICA INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in millions of U.S. dollars, except percentages and per share amounts)

(unaudited)

1
.             REPORTING ENTITY

Celestica Inc. (Celestica) is incorporated in Ontario with its corporate headquarters located in Toronto, Ontario, Canada. Celestica’s subordinate voting shares (SVS) are listed on the Toronto Stock Exchange (TSX) and the New York Stock Exchange (NYSE).

2
.             BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICIES

Statement of compliance:

These unaudited interim condensed consolidated financial statements for the quarter ended March 31, 2023 (Q1 2023 Interim Financial Statements) have been prepared in accordance with International Accounting Standard (IAS) 34, Interim Financial Reporting, and the accounting policies we have adopted in accordance with International Financial Reporting Standards (IFRS), in each case as issued by the International Accounting Standards Board (IASB), and reflect all adjustments that are, in the opinion of management, necessary to present fairly our financial position as of March 31, 2023 and our financial performance, comprehensive income and cash flows for the three months ended March 31, 2023 (referred to herein as Q1 2023). The Q1 2023 Interim Financial Statements should be read in conjunction with our 2022 audited consolidated financial statements (2022 AFS), which are included in our Annual Report on Form 20-F for the year ended December 31, 2022. The Q1 2023 Interim Financial Statements are presented in United States (U.S.) dollars, which is also Celestica’s functional currency. Unless otherwise noted, all financial information is presented in millions of U.S. dollars (except percentages and per share amounts).

The Q1 2023 Interim Financial Statements were authorized for issuance by our board of directors on April 26, 2023.

Use of estimates and judgments:

The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies, the reported amounts of assets, liabilities, revenue and expenses, and related disclosures with respect to contingent assets and liabilities. We base our judgments, estimates and assumptions on current facts (including, in recent periods, the prolonged impact of global supply chain constraints and the impact of the fire event in June 2022 described in note 12), historical experience and various other factors that we believe are reasonable under the circumstances. The economic environment also impacts certain estimates and discount rates necessary to prepare our consolidated financial statements, including significant estimates and discount rates applicable to the determination of the recoverable amounts used in the impairment testing of our non-financial assets. Our assessment of these factors forms the basis for our judgments on the carrying values of our assets and liabilities, and the accrual of our costs and expenses. Actual results could differ materially from our estimates and assumptions. We review our estimates and underlying assumptions on an ongoing basis and make revisions as determined necessary by management. Revisions are recognized in the period in which the estimates are revised and may also impact future periods.

Our review of the estimates, judgments and assumptions used in the preparation of the Q1 2023 Interim Financial Statements included those relating to, among others: our determination of the timing of revenue recognition, the determination of whether indicators of impairment existed for our assets and cash generating units (CGUs¹), our measurement of deferred tax assets and liabilities, our estimated inventory write-downs and expected credit losses, and customer creditworthiness. Any revisions to estimates, judgments or assumptions may result in, among other things, write-downs, accelerated depreciation or amortization, or impairment of our assets or CGUs, and/or adjustments to the carrying amount of our accounts receivable and/or inventories, or to the valuation of our deferred tax assets, any of which could have a material impact on our financial performance and financial condition.

Accounting policies:

Except for Amendments to IAS 1 and IFRS Practice Statement 2, adopted as of January 1, 2023 as described below, the Q1 2023 Interim Financial Statements are based on accounting policies consistent with those described in note 2 to our 2022 AFS.

___________________________________

¹ CGUs are the smallest identifiable group of assets that cannot be tested individually and generate cash inflows that are largely independent of those of other assets or groups of assets, and can be comprised of a single site, a group of sites, or a line of business.

Recently issued accounting standards and amendments:

Classification of liabilities as current or non-current (Amendments to IAS 1)

In January 2020, the IASB issued Classification of liabilities as current or non-current (Amendments to IAS 1) to clarify how to classify debt and other liabilities as current or non-current. The amendments are effective for reporting periods beginning on or after January 1, 2024. We will adopt this standard as of January 1, 2024, and are in the process of evaluating the impact of the adoption of this standard on our consolidated financial statements.

Definition of accounting estimates (Amendments to IAS 8)

In February 2021, the IASB issued Definition of accounting estimates (Amendments to IAS 8) to clarify the distinction between accounting policies and accounting estimates. The amendments are effective for reporting periods beginning on or after January 1, 2023. We adopted this standard as of January 1, 2023. The adoption of this standard had no material impact on our consolidated financial statements.

Making Materiality Judgements (Amendments to IAS 1 and IFRS Practice Statement 2)

In February 2021, the IASB issued amendments to IAS 1 and IFRS Practice Statement 2 “Making Materiality Judgements”, which provide guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments aim to help entities provide accounting policy disclosures that are more useful by replacing the requirement for entities to disclose their “significant” accounting policies with a requirement to disclose their material accounting policies and adding guidance on how entities are to apply the concept of materiality in making decisions about accounting policy disclosures. These amendments are applicable for annual periods beginning on or after January 1, 2023. These amendments, which we adopted as of such date, had no material impact and will be reflected in our 2023 consolidated financial statements.

Deferred tax related to assets and liabilities arising from a single transaction (Amendments to IAS 12 Income Taxes)

In May 2021, the IASB issued Deferred tax related to assets and liabilities arising from a single transaction (Amendments to IAS 12 Income Taxes) to clarify how to account for deferred tax on transactions such as leases and decommissioning obligations. The amendments are effective for reporting periods beginning on or after January 1, 2023. We adopted this standard as of January 1, 2023. The adoption of this standard had no material impact on our consolidated financial statements.

IFRS 17 Insurance Contracts

In May 2017, the IASB issued IFRS 17 Insurance Contracts. IFRS 17 replaces IFRS 4 and sets out principles for the recognition, measurement, presentation and disclosure of insurance contracts within the scope of IFRS 17. This standard is effective for reporting periods beginning on or after January 1, 2023. We adopted this standard as of January 1, 2023. The adoption of this standard had no material impact on our consolidated financial statements.

3

.  

         SEGMENT AND CUSTOMER REPORTING

Segments:

Celestica delivers innovative supply chain solutions globally to customers in two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity & Cloud Solutions (CCS). Our ATS segment consists of our ATS end market, and is comprised of our Aerospace and Defense (A&D), Industrial, HealthTech and Capital Equipment businesses. Our CCS segment consists of our Communications and Enterprise (servers and storage) end markets. See note 25 to our 2022 AFS for a description of the businesses that comprise our segments. Segment performance is evaluated based on segment revenue, segment income and segment margin (segment income as a percentage of segment revenue). Segment income is defined as a segment’s net revenue less its cost of sales and its allocable portion of selling, general and administrative expenses and research and development expenses (collectively, Segment Costs). Identifiable Segment Costs are allocated directly to the applicable segment while other Segment Costs, including indirect costs and certain corporate charges, are allocated to our segments based on an analysis of the relative usage or benefit derived by each segment from such costs. Segment income for the periods set forth below excludes finance costs (defined in note 6), employee stock-based compensation (SBC) expense, amortization of intangible assets (excluding computer software), and other charges (the components of which are described in note 8), as these costs and charges are managed and reviewed by our Chief Executive Officer (CEO) at the company level. In December 2022, we entered into a total return swap (TRS) agreement (TRS Agreement). Commencing in Q1 2023, TRS fair value adjustments (TRS FVAs) are also excluded in our determination of segment income, as similar to employee SBC expense, they are managed and reviewed by our CEO at the company level. Although segment income and segment margin are used to evaluate the performance of our segments, we may incur operating costs in one segment that may also benefit the other segment. Our accounting policies for segment reporting are the same as those applied to Celestica as a whole.

Information regarding the performance of our reportable segments is set forth below:

Revenue by segment:	Three months ended March 31
	2022					2023
			% of total					% of total
ATS	$	696.7	44	%		$	792.2	43	%
CCS		870.2	56	%			1,045.6	57	%
Communications end market revenue as a % of total revenue			38	%				36	%
Enterprise end market revenue as a % of total revenue			18	%				21	%
Total	$	1,566.9				$	1,837.8

Segment income, segment margin, and reconciliation of segment income to IFRS earnings before income taxes:		Three months ended March 31
	Note	2022					2023
				Segment Margin					Segment Margin
ATS segment income and margin		$	35.1	5.0	%		$	34.6	4.4	%
CCS segment income and margin			34.2	3.9	%			60.8	5.8	%
Total segment income			69.3					95.4
Reconciling items:
Finance costs	6		9.8					21.7
Employee SBC expense			14.6					22.0
TRS FVAs	10		—					0.2
Amortization of intangible assets (excluding computer software)			9.3					9.2
Other charges	8		4.8					4.6
IFRS earnings before income taxes		$	30.8				$	37.7

Customers:

Two customers (each in our CCS segment) individually represented 10% or more of total revenue in Q1 2023 (15% and 11%). No individual customer represented 10% or more of total revenue in the first quarter of 2022 (Q1 2022).

Seasonality:

From time to time, we experience some level of seasonality in our quarterly revenue patterns across certain of our businesses. Typically, revenue from our Enterprise end market decreases in the first quarter of the year compared to the previous quarter, and then increases in the second quarter, reflecting an increase in customer demand. We also typically experience our lowest overall revenue levels during the first quarter of each year. There can be no assurance that these patterns will continue. The addition of new customers has also introduced different demand cycles from our existing customers, creating more volatility and unpredictability in our revenue patterns. These and other factors make it difficult to isolate the impact of seasonality on our business.

4
.             ACCOUNTS RECEIVABLE

Accounts receivable (A/R) sales program and supplier financing programs (SFPs):

We are party to an A/R sales program agreement with a third-party bank to sell up to $450.0 (as amended at the end of March 2023 to increase the prior limit of $405.0) in A/R on an uncommitted, revolving basis, subject to pre-determined limits by customer. This agreement provides for automatic annual one-year extensions, and may be terminated at any time by the bank or by us upon 3 months’ prior notice, or by the bank upon specified defaults. Under our A/R sales program, we continue to collect cash from our customers and remit amounts collected to the bank weekly.

As of March 31, 2023, we participate in three customer SFPs, pursuant to which we sell A/R from the relevant customer to third-party banks on an uncommitted basis. The SFPs have an indefinite term and may be terminated at any time by the customer or by us upon specified prior notice. Under our SFPs, the third-party banks collect the relevant A/R directly from these customers.

At March 31, 2023, we sold $282.6 of A/R (December 31, 2022 — $245.6) under our A/R sales program, and $128.2 of A/R (December 31, 2022 — $105.6) under the SFPs. The A/R sold under each of these programs are de-recognized from our A/R balance at the time of sale, and the proceeds are reflected as cash provided by operating activities in our consolidated statement of cash flows. Upon sale, we assign the rights to the A/R to the banks. A/R are sold net of discount charges, which are recorded as finance costs in our consolidated statement of operations.

Contract assets:

At March 31, 2023, our A/R balance included $268.1 (December 31, 2022 — $292.9) of contract assets recognized as revenue in accordance with our revenue recognition accounting policy.

5
.             INVENTORIES

We record inventory write-downs, net of valuation recoveries, in cost of sales. Inventories are valued at the lower of cost and net realizable value. Inventory write-downs reflect the write-down of inventory to its net realizable value. Valuation recoveries primarily reflect gains on the disposition of previously written-down inventory. We recorded net inventory write-downs of $13.8 for Q1 2023 (Q1 2022 — $2.5). The accounting treatment of inventories destroyed in a fire event in June 2022 is described in note 12.

We receive cash deposits from certain of our customers primarily to help mitigate the impact of higher inventory levels carried due to the current constrained materials environment, and to reduce risks related to excess and/or obsolete inventory. Such deposits as of March 31, 2023 totaled $810.8 (December 31, 2022 — $825.6), and were recorded in accrued and other current liabilities on our consolidated balance sheet.

6
.          CREDIT FACILITIES AND LEASE OBLIGATIONS

We are party to a credit agreement (Credit Facility) with Bank of America, N.A., as Administrative Agent, and the other lenders party thereto, which includes a term loan in the original principal amount of $350.0 (Initial Term Loan), a term loan in the original principal amount of $365.0 (Incremental Term Loan), and a $600.0 revolving credit facility (Revolver). The Initial Term Loan and the Incremental Term Loan are collectively referred to as the Term Loans.

The Initial Term Loan matures in June 2025. The Incremental Term Loan and the Revolver each mature in March 2025, unless either (i) the Initial Term Loan has been prepaid or refinanced or (ii) commitments under the Revolver are available and have been reserved to repay the Initial Term Loan in full, in which case the Incremental Term Loan and Revolver each mature in December 2026.

The Credit Facility has an accordion feature that allows us to increase the Term Loans and/or commitments under the Revolver by $150.0, plus an unlimited amount to the extent that a specified leverage ratio on a pro forma basis does not exceed specified limits, in each case on an uncommitted basis and subject to the satisfaction of certain terms and conditions.

Borrowings under the Revolver bear interest, depending on the currency of the borrowing and our election for such currency, at LIBOR, Base Rate, Canadian Prime, an Alternative Currency Daily Rate, or an Alternative Currency Term Rate (each as defined in the Credit Facility) plus a specified margin. The margin for borrowings under the Revolver and the Incremental Term Loan ranges from 1.50% — 2.25% for LIBOR borrowings and Alternative Currency borrowings, and between 0.50% — 1.25% for Base Rate and Canadian Prime borrowings, in each case depending on the rate we select and our consolidated leverage ratio (as defined in the Credit Facility). Commitment fees range between 0.30% and 0.45% depending on our consolidated leverage ratio. The Initial Term Loan currently bears interest at LIBOR plus 2.125%. The Incremental Term Loan currently bears interest at LIBOR plus 2.0%. See note 10 for a description of the LIBOR successor provisions under the Credit Facility.

The Incremental Term Loan requires quarterly principal repayments of $4.5625, and each of the Term Loans requires a lump sum repayment of the remainder outstanding at maturity. The Initial Term Loan required quarterly principal repayments of $0.875, all of which have been paid in prior years. We are also required to make annual prepayments of outstanding obligations under the Credit Facility (applied first to the Term Loans, then to the Revolver, in the manner set forth in the Credit Facility) ranging from 0% — 50% (based on a defined leverage ratio) of specified excess cash flow for the prior fiscal year. No prepayments based on 2022 excess cash flow will be required in 2023. In addition, prepayments of outstanding obligations under the Credit Facility (applied as described above) may also be required in the amount of specified net cash proceeds received above a specified annual threshold (including proceeds from the disposal of certain assets). No Credit Facility prepayments based on 2022 net cash proceeds will be required in 2023. Any outstanding amounts under the Revolver are due at maturity.

Activity under our Credit Facility during 2022 and Q1 2023 is set forth below:

	Revolver (1)			Term loans
Outstanding balances as of December 31, 2021	$	—		$	660.4
Amount repaid in Q1 2022(2)		—			(4.5625	)
Amount repaid in Q2 2022(2)		—			(4.5625	)
Amount repaid in Q3 2022(2)		—			(4.5625	)
Amount repaid in Q4 2022(3)		—			(19.5625	)
Outstanding balances as of December 31, 2022	$	—		$	627.2
Amount repaid in Q1 2023(2)		—			(4.5625	)
Outstanding balances as of March 31, 2023	$	—		$	622.6

 

(1)	In addition to the activity described in this table, we have drawn on the Revolver for short term borrowings from time-to-time during the periods set forth above and repaid such borrowings in full within the quarter borrowed, with no impact to the amounts outstanding at the relevant quarter-end. Such intra-quarter borrowings and repayments are excluded from this table.
(2)	Represents the scheduled quarterly principal repayment under the Incremental Term Loan.
(3)	Represents the scheduled quarterly principal repayment under the Incremental Term Loan and a $15.0 voluntary prepayment under the Initial Term Loan.

At March 31, 2023 and December 31, 2022, we were in compliance with all restrictive and financial covenants under the Credit Facility.

The following tables set forth, at the dates shown: outstanding borrowings under the Credit Facility, excluding ordinary course letters of credit (L/Cs); notional amounts under our interest rate swap agreements; and outstanding lease obligations:

	Outstanding borrowings								Notional amounts under interest rate swaps (note 10 )
	December 31 2022				March 31 2023				December 31 2022			March 31 2023
Borrowings under the Revolver	$	—			$	—			$	—		$	—
Borrowings under term loans:
Initial Term Loan	$	280.4			$	280.4			$	100.0		$	100.0
Incremental Term Loan		346.8				342.2				230.0			230.0
Total	$	627.2			$	622.6			$	330.0		$	330.0
Total borrowings under Credit Facility	$	627.2			$	622.6
Unamortized debt issuance costs related to our term loans(1)		(3.5	)			(3.3	)
Lease obligations(2)		162.4				155.9
	$	786.1			$	775.2
Total Credit Facility and lease obligations:
Current portion	$	52.2			$	51.1
Long-term portion		733.9				724.1
	$	786.1			$	775.2

 

(1)	We incur debt issuance costs upon execution of, subsequent security arrangements under, and amendments to the Credit Facility. No debt issuance costs were incurred in Q1 2023. Debt issuance costs of $0.3 incurred in Q1 2022 in connection with our Revolver were deferred as other assets on our consolidated balance sheet and are amortized on a straight line basis over the remaining term of the Revolver. Debt issuance costs of $0.3 incurred in Q1 2022 in connection with our Term Loans were deferred as long-term debt on our consolidated balance sheet and are amortized over their respective terms using the effective interest rate method.
(2)	These lease obligations represent the present value of unpaid lease payment obligations recognized as liabilities as of December 31, 2022 and March 31, 2023, respectively, which have been discounted using our incremental borrowing rate on the lease commencement dates. In addition to these lease obligations, we have commitments under additional real property leases not recognized as liabilities as of March 31, 2023 because such leases had not yet commenced as of such date. A description of these leases and minimum lease obligations thereunder are disclosed in note 24 to the 2022 AFS.

The following table sets forth, at the dates shown, information regarding outstanding L/Cs, surety bonds and overdraft facilities:

	December 31  2022			March 31  2023
Outstanding L/Cs under the Revolver	$	18.0		$	17.3
Outstanding L/Cs and surety bonds outside the Revolver		23.8			16.4
Total	$	41.8		$	33.7
Available uncommitted bank overdraft facilities	$	198.5		$	198.5
Amounts outstanding under available uncommitted bank overdraft facilities	$	—		$	—

Finance costs consist of interest expense and fees related to our Credit Facility (including debt issuance and related amortization costs), our interest rate swap agreements, our TRS Agreement, our A/R sales program and the SFPs, and interest expense on our lease obligations, net of interest income earned.

7
.            CAPITAL STOCK

SVS Repurchase Plans:

In recent years, we have repurchased SVS in the open market, or as otherwise permitted, for cancellation through normal course issuer bids (NCIBs), which allow us to repurchase a limited number of SVS during a specified period. The maximum number of SVS we are permitted to repurchase for cancellation under each NCIB is reduced by the number of SVS we arrange to be purchased by any non-independent broker in the open market during the term of such NCIB to satisfy delivery obligations under our SBC plans. We from time-to-time enter into automatic share purchase plans (ASPPs) with a broker, instructing the broker to purchase our SVS in the open market on our behalf, either for cancellation under an NCIB (NCIB ASPPs) or for delivery obligations under our SBC plans (SBC ASPPs), including during any applicable trading blackout periods, up to specified maximums (and subject to certain pricing and other conditions) through the term of each ASPP.

On December 2, 2021, the TSX accepted our notice to launch an NCIB (2021 NCIB), which allowed us to repurchase, at our discretion, from December 6, 2021 until the earlier of December 5, 2022 or the completion of purchases thereunder, up to approximately 9.0 million of our SVS in the open market, or as otherwise permitted, subject to the normal terms and limitations of such bids. We entered into an NCIB ASPP in December 2021, which has since expired. As of December 31, 2021, we accrued $7.5, representing the estimated contractual maximum number of permitted SVS repurchases (Contractual Maximum Quantity) under the December 2021 NCIB ASPP (0.7 million SVS), which was reversed in Q1 2022. In December 2021, we entered into an SBC ASPP, which has since expired. We recorded an accrual as of December 31, 2021 of $33.8, representing the estimated Contractual Maximum Quantity (3.0 million SVS) under the December 2021 SBC ASPP, which was reversed in Q1 2022.

On December 8, 2022, the TSX accepted our notice to launch another NCIB (2022 NCIB). The 2022 NCIB allows us to repurchase, at our discretion, from December 13, 2022 until the earlier of December 12, 2023 or the completion of purchases thereunder, up to approximately 8.8 million of our SVS in the open market, or as otherwise permitted, subject to the normal terms and limitations of such bids. As of March 31, 2023, approximately 7.7 million SVS remain available for repurchase under the 2022 NCIB either for cancellation or SBC delivery purposes. In December 2022, we entered into an NCIB ASPP that expired prior to December 31, 2022 (such that no accrual was recorded as of December 31, 2022). We recorded an accrual as of March 31, 2023 of $5.0 (March 2023 NCIB Accrual), representing the contractual maximum spend for SVS repurchases for cancellation under an NCIB ASPP executed in February 2023.

SVS repurchased in Q1 2023 and Q1 2022 for cancellation and for SBC plan delivery obligations (including under ASPPs) are set forth in the chart below.

SVS repurchases:

	Three months ended March 31
	2022			2023
Aggregate cost(1) of SVS repurchased for cancellation(2)	$	7.8		$	10.6
Number of SVS repurchased for cancellation (in millions)(3)		0.7			0.8
Weighted average price per share for repurchases	$	11.50		$	13.12
Aggregate cost(1) of SVS repurchased for delivery under SBC plans (see below)	$	34.8		$	—
Number of SVS repurchased for delivery under SBC plans (in millions)(4)		3.0			—

⁽¹⁾   Includes transaction fees.
⁽²⁾   For Q1 2023, excludes the $5.0 March 2023 NCIB Accrual.
⁽³⁾   For Q1 2022 and Q1 2023, includes 0.2 million and 0.4 million NCIB ASPP purchases of SVS for cancellation, respectively.
⁽⁴⁾   For Q1 2022, consists entirely of SBC ASPP purchases.

SBC:

From time to time, we pay cash to a broker to purchase SVS in the open market to satisfy delivery requirements under our SBC plans. At March 31, 2023, the broker held 0.9 million SVS with a value of $10.3 (December 31, 2022 — 1.5 million SVS with a value of $16.7) for this purpose, which we report as treasury stock on our consolidated balance sheet. We used 0.6 million SVS held by the broker to settle SBC awards during Q1 2023.

We grant restricted share units (RSUs) and performance share units (PSUs), and from time-to-time stock options, to employees under our SBC plans. The majority of RSUs vest one-third per year over a three-year period. Stock options generally vest 25% per year over a four-year period. The number of outstanding PSUs that will actually vest varies from 0% to 200% of a target amount granted. For PSUs granted in 2020, 2021 and 2022, the number of PSUs that vested (or will vest) are based on the level of achievement of a pre-determined non-market performance measurement in the final year of the relevant three-year performance period, subject to modification by each of a separate pre-determined non-market financial target, and our relative total shareholder return (TSR), a market performance condition, compared to a pre-defined group of companies, in each case over the relevant three-year performance period. For PSUs granted in Q1 2023, the number of PSUs that will vest are based on the level of achievement of a different predetermined non-market performance measurement, subject to modification by our relative TSR compared to a pre-defined group of companies, in each case over the relevant three-year performance period. We also grant deferred share units (DSUs) and RSUs (under specified circumstances) to directors as compensation under our Directors’ Share Compensation Plan. See note 2(l) to the 2022 AFS for further detail.

Information regarding RSU, PSU and DSU grants to employees and directors, as applicable, for the periods indicated is set forth below (no stock options were granted in either period):

	Three months ended March 31
	2022			2023
RSUs Granted:
Number of awards (in millions)		1.7			1.8
Weighted average grant date fair value per unit	$	12.42		$	12.75
PSUs Granted:
Number of awards (in millions, representing 100% of target)		1.2			1.3
Weighted average grant date fair value per unit	$	14.40		$	15.01
DSUs Granted:
Number of awards (in millions)		0.03			0.03
Weighted average grant date fair value per unit	$	11.91		$	12.90

In Q1 2023, we settled a portion of RSUs and PSUs that vested during the quarter with a cash payment of $49.8. Since those awards may be settled either in cash or SVS at the discretion of Celestica, we accounted for them as equity-settled awards.

In December 2022, we entered into the TRS Agreement to manage cash flow requirements and our exposure to fluctuations in the share price of our SVS in connection with the settlement of certain outstanding equity awards under our SBC plans. See note 10 for further detail.

Information regarding employee and director SBC expense and TRS FVAs for the periods indicated is set forth below:

	Three months ended March 31
	2022			2023
Employee SBC expense in cost of sales	$	5.6		$	8.5
Employee SBC expense in SG&A		9.0			13.5
Total employee SBC expense	$	14.6		$	22.0
TRS FVAs in cost of sales	$	—		$	0.1
TRS FVAs in SG&A		—			0.1
Total TRS FVAs	$	—		$	0.2
Sum of employee SBC expense and TRS FVAs	$	14.6		$	22.2
Director SBC expense in SG&A(1)	$	0.6		$	0.6

⁽¹⁾ Expense consists of director compensation to be settled with SVS, or SVS and cash, as elected by each director.

8
.             OTHER CHARGES

	Three months ended March 31
	2022			2023
Restructuring charges (a)	$	3.1		$	4.3
Transition Costs (b)		1.5			—
Acquisition Costs (c)		0.2			0.3
	$	4.8		$	4.6

(a)
        Restructuring:

Our restructuring activities for Q1 2023 consisted primarily of actions to adjust our cost base to address reduced levels of demand in certain of our businesses and geographies.

In Q1 2023, we recorded $4.3 of cash restructuring charges, primarily for employee termination costs, and nil non-cash restructuring charges. In Q1 2022, we recorded $2.8 of cash restructuring charges, primarily for employee termination costs, and $0.3 of non-cash restructuring charges, primarily for the accelerated depreciation of assets related to disengaging programs. At March 31, 2023, our restructuring provision was $7.0 (December 31, 2022 — $5.8), which we recorded in the current portion of provisions on our consolidated balance sheet.

(b)
        Transition Costs:

Transition Costs consist of costs recorded in connection with: (i) the transfer of manufacturing lines from closed sites to other sites within our global network; and (ii) the sale of real properties unrelated to restructuring actions. Transition Costs consist of direct relocation and duplicate costs (such as rent expense, utility costs, depreciation charges, and personnel costs) incurred during the transition periods, as well as cease-use and other costs incurred in connection with idle or vacated portions of the relevant premises that we would not have incurred but for these relocations, transfers and dispositions. We incurred nil Transition Costs during Q1 2023, and $1.5 of Transition Costs in Q1 2022 related to the then-anticipated disposal of certain assets reclassified as held for sale during Q1 2022.

(c)
        Acquisition Costs:

We incur consulting, transaction and integration costs relating to potential and completed acquisitions. We also incur charges or releases related to the subsequent re-measurement of indemnification assets or the release of indemnification or other liabilities recorded in connection with acquisitions, when applicable. Collectively, these costs, charges and releases are referred to as Acquisition Costs (Recoveries).

We recorded $0.3 of Acquisition Costs in Q1 2023 related to potential acquisitions, and $0.2 of Acquisition Costs in Q1 2022 related to the acquisition of PCI Private Limited (acquired in November 2021).

9
.         INCOME TAXES

Our income tax expense or recovery for each quarter is determined by multiplying the earnings or losses before tax for such quarter by management’s best estimate of the weighted-average annual income tax rate expected for the full year, taking into account the tax effect of certain items recognized in the interim period. As a result, the effective income tax rates used in our interim financial statements may differ from management’s estimate of the annual effective tax rate for the annual financial statements. Our estimated annual effective income tax rate varies as the quarters progress, for various reasons, including as a result of the mix and volume of business in various tax jurisdictions within the Americas, Europe and Asia, in jurisdictions with tax holidays and tax incentives, and in jurisdictions for which no net deferred income tax assets have been recognized because management believes it is not probable that future taxable profit will be available against which tax losses and deductible temporary differences could be utilized. Our annual effective income tax rate can also vary due to the impact of restructuring charges, foreign exchange fluctuations, operating losses, cash repatriations, and changes in our provisions related to tax uncertainties.

Our Q1 2023 net income tax expense of $13.0 was favorably impacted by $5.5 in reversals of tax uncertainties in one of our Asian subsidiaries, partially offset by a $1.3 tax expense arising from taxable temporary differences associated with the anticipated repatriation of undistributed earnings from certain of our Chinese subsidiaries. Taxable foreign exchange impacts were not significant in Q1 2023.

Our Q1 2022 net income tax expense of $9.0 was favorably impacted by $4.9 in reversals of tax uncertainties in one of our Asian subsidiaries. Taxable foreign exchange impacts were not significant in Q1 2022.

10
.          FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

Our financial assets are comprised primarily of cash and cash equivalents, A/R, and derivatives used for hedging purposes. Our financial liabilities are comprised primarily of accounts payable, certain accrued and other liabilities, the Term Loans, borrowings under the Revolver, lease obligations, and derivatives. 

Equity price risk:

In December 2022, we entered into the TRS Agreement with a third-party bank with respect to a notional amount of 3.0 million of our SVS (Notional Amount) to manage our cash flow requirements and exposure to fluctuations in the price of our SVS in connection with the settlement of certain outstanding equity awards under our SBC plans. The counterparty under the TRS Agreement is obligated to make a payment to us upon its termination (in whole or in part) or expiration (Settlement) based on the increase (if any) in the value of the TRS (as defined in the TRS Agreement) over the agreement’s term, in exchange for periodic payments made by us based on the counterparty’s SVS purchase costs and a variable interest rate plus a specified margin. Similarly, if the value of the TRS (as defined in the TRS Agreement) decreases over the term of the TRS Agreement, we are obligated to pay the counterparty the amount of such decrease upon Settlement. The change in value of the TRS is determined by comparing the average amount realized by the counterparty upon the disposition of purchased SVS to the average amount paid for such SVS. As of March 31, 2023, the counterparty had acquired the entire Notional Amount at a weighted average price of $12.73 per share. The TRS Agreement provides for automatic annual one-year extensions (subject to specified conditions), and may be terminated by either party at any time. The TRS does not qualify for hedge accounting. As of March 31, 2023, the fair value of TRS Agreement was an unrealized loss of $0.2, which we recorded in accrued and other current liabilities on our consolidated balance sheet. TRS FVAs (representing the change of fair value of TRS) are recognized in our consolidated statement of operations each quarter. See note 7 for TRS FVAs in Q1 2023.

Interest rate risk:

Borrowings under the Credit Facility expose us to interest rate risk due to the potential variability of market interest rates. In order to partially hedge against our exposure to interest rate variability on our Term Loans, we have entered into various agreements with third-party banks to swap the variable interest rate (based on LIBOR plus a margin) with a fixed rate of interest for a portion of the borrowings under our Term Loans. At March 31, 2023, we had: (i) interest rate swaps hedging the interest rate risk associated with $100.0 of our Initial Term Loan borrowings that expire in August 2023 (Initial Swaps); (ii) interest rate swaps hedging the interest rate risk associated with $100.0 of our Initial Term Loan borrowings, for which the cash flows commence upon the expiration of the Initial Swaps and continue through June 2024 (First Extended Initial Swaps); (iii) interest rate swaps hedging the interest rate risk associated with $100.0 of our Initial Term Loan borrowings (and any subsequent term loans replacing the Initial Term Loan), for which the cash flows commence upon the expiration of the First Extended Initial Swaps and continue through December 2025 (Second Extended Initial Swaps); (iv) interest rate swaps hedging the interest rate risk associated with $100.0 of outstanding borrowings under the Incremental Term Loan that expire in December 2023 (Incremental Swaps); (v) interest rate swaps hedging the interest rate risk associated with $100.0 of our Incremental Term Loan borrowings, for which the cash flows commence upon the expiration of the Incremental Swaps and continue through December 2025 (First Extended Incremental Swaps); and (vi) interest rate swaps hedging the interest rate risk associated with an additional $130.0 of our Incremental Term Loan borrowings that expire in December 2025 (Additional Incremental Swaps). We have an option to cancel up to $50.0 of the notional amount of the Additional Incremental Swaps from January 2024 through October 2025.   

At March 31, 2023, the interest rate risk related to $292.6 of borrowings under the Credit Facility was unhedged, consisting of unhedged amounts outstanding under the Term Loans ($180.4 under the Initial Term Loan and $112.2 under the Incremental Term Loan), and no amounts outstanding (other than ordinary course L/Cs) under the Revolver. See note 6.

At March 31, 2023, the fair value of our interest rate swap agreements was an unrealized gain of $15.1 (December 31, 2022 — an unrealized gain of $18.7), which we recorded in other current assets and other non-current assets on our consolidated balance sheet. The unrealized portion of the change in fair value of the swaps is recorded in other comprehensive income (loss) (OCI). The realized portion of the change in fair value of the swaps is released from accumulated OCI and recognized under finance costs in our consolidated statement of operations when the hedged interest expense is recognized.

Global reform of major interest rate benchmarks is currently underway, including the anticipated replacement of some Interbank Offered Rates (including LIBOR) with alternative nearly risk-free rates. See note 2, “Recently issued accounting standards and amendments” of the 2022 AFS. As at March 31, 2023, we have obligations under our Credit Facility and derivative instruments that are indexed to LIBOR (LIBOR Agreements). The interest rates under these agreements are subject to change when relevant LIBOR benchmark rates cease to exist. Remaining LIBOR settings are expected to expire after June 2023. However, there remains uncertainty over the methods of transition to such alternate rates.

Our Credit Facility provides that, with respect to the Initial Term Loan and any non-U.S. dollar-denominated borrowings under the Revolver, when the administrative agent, the majority of lenders or we determine that LIBOR (or the corresponding rate for any Alternative Currency, as defined in the Credit Facility), is unavailable or being replaced, then we and the administrative agent may amend the underlying credit agreement to reflect a successor rate as specified therein. The Credit Facility has not yet been so amended. Once LIBOR becomes unavailable: (i) if no successor rate has been established, LIBOR borrowings under the Initial Term Loan will convert to Base Rate loans, and any non-U.S. dollar-denominated borrowings under the Revolver will be repaid, replaced or converted pursuant to the Credit Facility, and (ii) LIBOR borrowings under the Incremental Term Loan and U.S. dollar-denominated borrowings under the Revolver will convert to secured overnight financing rate (SOFR) loans recommended or selected by the relevant governmental body, adjusted as set forth in the Credit Facility. It remains uncertain when the benchmark transitions will be complete or what replacement rates will be used.

Our variable rate Term Loans are partially hedged with interest rate swap agreements (described above). Hedge ineffectiveness could result due to the cessation of LIBOR, if such agreements transition using a different benchmark or spread adjustment as compared to the underlying hedged debt. The Second Extended Initial Swaps, the First Extended Incremental Swaps and the Additional Incremental Swaps mirror the LIBOR successor provisions under the Credit Facility, but have not yet transitioned to a successor rate. We have also amended the swap agreement with one of the two counterparty banks under the Incremental Swaps (with a notional amount of $50.0) to mirror the LIBOR successor provisions under the Credit Facility, but such swaps have not yet transitioned to the successor rate. Our remaining interest rate swap agreements do not yet have LIBOR successor provisions and will require future amendment. As a result, we cannot assure that benchmark transitions under these interest rate swap agreements will be successful, or if so, what replacement rates will be used.

Our A/R sales program and three customer SFPs that were indexed to LIBOR have transitioned to alternative benchmark rates with predetermined spreads. Our lease arrangements with progress payments that were indexed to LIBOR have transitioned to SOFR-based benchmark rates. These transitions did not have a significant impact on our consolidated financial statements. Our TRS Agreement bears interest based on SOFR.

While we expect that reasonable alternatives to LIBOR benchmarks will be implemented in advance of their cessation dates, we cannot assure that this will be the case. If relevant LIBOR benchmarks are no longer available and the alternative reference rate is higher, interest rates under the affected LIBOR Agreements would increase, which would adversely impact our interest expense, our financial performance and cash flows. We will continue to monitor developments with respect to the cessation of LIBOR, and will evaluate potential impacts on our LIBOR Agreements, processes, systems, risk management methodology and valuations, financial reporting, taxes, and financial results. However, we are currently unable to predict what the future replacement rates or consequences on our operations or financial results will be.

Currency risk:

The majority of our currency risk is driven by operational costs, including income tax expense, incurred in local currencies by our subsidiaries. We cannot predict changes in currency exchange rates, the impact of exchange rate changes on our operating results, nor the degree to which we will be able to manage the impact of currency exchange rate changes. Such changes could have a material effect on our business, financial performance and financial condition.

Our major currency exposures at March 31, 2023 are summarized in U.S. dollar equivalents in the following table. The local currency amounts have been converted to U.S. dollar equivalents using spot rates at March 31, 2023.

	Canadian dollar				Euro				Thai baht				Chinese renminbi				Mexican peso
Cash and cash equivalents	$	2.1			$	10.6			$	2.5			$	11.4			$	0.5
Accounts receivable		0.2				64.4				0.2				14.9				—
Income taxes and value-added taxes receivable		17.9				0.9				0.9				3.1				46.7
Other financial assets		—				3.9				0.6				0.3				2.0
Pension and non-pension post-employment liabilities		(49.0	)			(0.6	)			(19.1	)			(0.6	)			(3.7	)
Income taxes and value-added taxes payable		(18.1	)			(1.7	)			(4.9	)			(8.8	)			(9.1	)
Accounts payable and certain accrued and other liabilities and provisions		(44.5	)			(44.8	)			(32.7	)			(37.3	)			(14.7	)
Net financial assets (liabilities)	$	(91.4	)		$	32.7			$	(52.5	)		$	(17.0	)		$	21.7

We enter into foreign currency forward contracts to hedge our cash flow exposures and foreign currency swaps to hedge the exposures of our monetary assets and liabilities denominated in foreign currencies. While these contracts are intended to reduce the effects of fluctuations in foreign currency exchange rates, our hedging strategy does not mitigate the longer-term impacts of changes to foreign exchange rates.

At March 31, 2023, we had foreign currency forwards and swaps to trade U.S. dollars in exchange for the following currencies:

Currency	Contract amount in  U.S. dollars			Weighted average  exchange rate in  U.S. dollars (1)			Maximum  period in  months		Fair value  gain (loss)
Canadian dollar	$	207.0		$	0.75		13		$	(1.8	)
Thai baht		151.9			0.03		12			1.3
Malaysian ringgit		134.6			0.23		12			0.5
Mexican peso		70.1			0.05		12			2.0
British pound		2.2			1.22		4			—
Chinese renminbi		36.8			0.15		11			0.1
Euro		75.3			1.08		8			(0.7	)
Romanian leu		41.7			0.21		12			2.2
Singapore dollar		20.1			0.74		12			0.4
Japanese yen		5.0			0.0076		4			—
Korean won		4.5			0.0008		4			0.1
Total	$	749.2							$	4.1
Fair values of outstanding foreign currency forward and swap contracts related to effective cash flow hedges where we applied hedge accounting										7.1
Fair values of outstanding foreign currency forward and swap contracts related to economic hedges where we record the changes in the fair values of such contracts through our consolidated statement of operations										(3.0	)
									$	4.1

 

(1)	Represents the U.S. dollar equivalent (not in millions) of one unit of the foreign currency, weighted based on the notional amounts of the underlying foreign currency forward and swap contracts outstanding as at March 31, 2023.

At March 31, 2023, the aggregate fair value of our outstanding contracts was a net unrealized gain of $4.1 (December 31, 2022 — net unrealized gain of $5.2), resulting from fluctuations in foreign exchange rates between the contract execution and the period-end date. At March 31, 2023, we recorded $13.4 of derivative assets in other current assets and $9.3 of derivative liabilities in accrued and other current liabilities (December 31, 2022 — $18.9 of derivative assets in other current assets and $13.7 of derivative liabilities in accrued and other current liabilities).

Credit risk:

Credit risk refers to the risk that a counterparty may default on its contractual obligations resulting in a financial loss to us. We believe our credit risk of counterparty non-performance continues to be relatively low. We are in regular contact with our customers, suppliers and logistics providers, and have not experienced significant counterparty credit-related non-performance in 2022 or Q1 2023. However, if a key supplier (or any company within such supplier’s supply chain) or customer fails to comply with their contractual obligations, this could result in a significant financial loss to us. We would also suffer a significant financial loss if an institution from which we purchased foreign currency exchange contracts and swaps, interest rate swaps, or annuities for our pension plans, or which is a counterparty to our TRS Agreement, defaults on their contractual obligations. With respect to our financial market activities, we have adopted a policy of dealing only with counterparties we deem to be creditworthy. No significant adjustments were made to our allowance for doubtful accounts during Q1 2023 or Q1 2022 in connection with our ongoing credit risk assessments.

Liquidity risk:

Liquidity risk is the risk that we may not have cash available to satisfy our financial obligations as they come due. The majority of our financial liabilities recorded in accounts payable, accrued and other current liabilities and provisions are due within 90 days. We manage liquidity risk through maintenance of cash on hand and access to the various financing arrangements described in notes 4 and 6. We believe that cash flow from operating activities, together with cash on hand, cash from accepted sales of A/R, and borrowings available under the Revolver and potentially available under uncommitted intraday and overnight bank overdraft facilities, are sufficient to fund our currently anticipated financial obligations, and will remain available in the current environment. As our A/R sales program and SFPs are each uncommitted, however, there can be no assurance that any participant bank will purchase any of the A/R that we wish to sell.

11
.        
COMMITMENTS
AND CONTINGENCIES

Litigation:

In the normal course of our operations, we may be subject to lawsuits, investigations and other claims, including environmental, labor, product, customer disputes, and other matters. Management believes that adequate provisions have been recorded where required. Although it is not always possible to estimate the extent of potential costs, if any, we believe that the ultimate resolution of all such pending matters will not have a material adverse impact on our financial performance, financial position or liquidity.

Taxes and Other Matters:

In the third quarter of 2021 (Q3 2021), the Romanian tax authorities issued a final assessment in the aggregate amount of approximately 31 million Romanian leu (approximately $7 at period-end exchange rates), for additional income and value-added taxes for one of our Romanian subsidiaries for the 2014 to 2018 tax years. In order to advance our case to the appeals phase and reduce or eliminate potential interest and penalties, we paid the Romanian tax authorities the full amount assessed in Q3 2021 (without agreement to all or any portion of such assessment). We believe that our originally-filed tax return positions are in compliance with applicable Romanian tax laws and regulations, and intend to vigorously defend our position through all necessary appeals or other judicial processes.

The successful pursuit of assertions made by any government authority, including tax authorities, could result in our owing significant amounts of tax or other reimbursements, interest and possibly penalties. We believe we adequately accrue for any probable potential adverse ruling. However, there can be no assurance as to the final resolution of any claims and any resulting proceedings. If any claims and any ensuing proceedings are determined adversely to us, the amounts we may be required to pay could be material, and in excess of amounts accrued.

12
.        FIRE EVENT

In June 2022, a fire occurred at our Batam, Indonesia facility. The fire destroyed inventories and damaged a building and equipment located at the site. Our manufacturing operations at the site were briefly paused, but resumed in June 2022. In 2022, we wrote down inventories destroyed (approximately $94) and a building and equipment damaged (approximately $1) by the fire. We expect to fully recover our tangible losses pursuant to the terms and conditions of our insurance policies. In the fourth quarter of 2022 and Q1 2023, we recovered $31 and $2 of our inventory losses through insurance proceeds, respectively. As of March 31, 2023, we recorded an estimated receivable of approximately $62 related to remaining anticipated insurance proceeds in other current assets on our consolidated balance sheet. The write-downs and the offsetting insurance receivable (in equivalent amounts) were each recorded in other charges in 2022, resulting in no net impact to net earnings. We determined that this event did not constitute an impairment review triggering event for the applicable CGU, and no impairments to our intangibles or goodwill were recorded in connection therewith in 2022 or Q1 2023.

Contacts:
Celestica Global Communications
(416) 448-2200
[email protected]

Celestica Investor Relations
(416) 448-2211
[email protected]

Multiple Myeloma

• 92% was the overall response rate produced by NXC-201 in relapsed/refractory multiple myeloma patients treated at the therapeutic dose of 800 million CAR+T cells in its ongoing phase 1b/2a NEXICART-1 clinical trial (NCT04720313) who were not exposed to prior BCMA-targeted therapy, producing a median progression free survival (mPFS) of 12.3 months as of the February 9, 2023 data cutoff
• The $13.9 billion Multiple Myeloma market in 2017 is expected to reach $28.7 billion in 2027 according to Wilcock, et al. Nature Reviews
• Nexcella plans to submit a BLA for FDA approval in multiple myeloma once 100 patients are treated with NXC-201
• The expected primary endpoint for NXC-201 in relapsed/refractory multiple myeloma is overall response rate

AL Amyloidosis

• 100% (8/8) was the overall response rate produced by NXC-201 in 8 light chain (AL) amyloidosis patients in our ongoing phase 1b/2a NEXICART-1 clinical trial (NCT04720313)
• The Amyloidosis market was $3.6 billion in 2017, expected to reach $6 billion in 2025, according to Grand View Research
• The expected primary endpoint for a pivotal study of NXC-201 in relapsed/refractory AL Amyloidosis is overall response rate
• Nexcella plans to submit a BLA for FDA approval in AL amyloidosis once 30-40 patients are treated with NXC-201

Nexcella Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49



^th Annual Meeting in Paris

Nexcella, Inc. a subsidiary of Immix Biopharma, Inc. (NASDAQ:IMMX)

LOS ANGELES, April 26, 2023 (GLOBE NEWSWIRE) — Nexcella Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), today announced new positive clinical data from its ongoing Phase 1b/2 NEXICART-1 (NCT04720313) study of its novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 for the treatment of patients with relapsed or refractory light chain (AL) amyloidosis and multiple myeloma. The dataset represents 8 new evaluable patients in multiple myeloma and 3 new evaluable patients in light chain (AL) amyloidosis (paper and poster publications www.nexcella.com/publications). The new data are being presented during a poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting in Paris, France, April 23-26.

“We continue to be very encouraged by NXC-201 clinical results,” said Polina Stepensky, M.D., Director of the Hadassah Medical Organization’s Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, and principal study investigator. “In multiple myeloma, these data are compelling as the overall response rate for ABECMA was 72% in its pivotal KarMMa trial with 100 patients in relapsed or refractory multiple myeloma. In AL Amyloidosis, NXC-201’s very promising response could offer hope to patients who have already been treated with a 4-drug standard-of-care combination incorporating DARZALEX.  In particular, NXC-201 may offer a valuable option for both multiple myeloma and AL amyloidosis patients who have progressed on standards of care.”

As of the February 9, 2023 data cutoff, updated clinical data in 58 patients from the ongoing NEXICART-1 (NCT04720313) study of the novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 for the treatment of relapsed or refractory multiple myeloma and light chain amyloidosis (AL) was presented. At all doses of NXC-201 across 50 patients, median follow-up was 5.7 months (range: 0.6-17.5 months). NXC-201 clinical data showed:

Multiple Myeloma

• 92% was the overall response rate produced by NXC-201 in relapsed/refractory multiple myeloma patients treated at the therapeutic dose of 800 million CAR+T cells in its ongoing phase 1b/2a NEXICART-1 clinical trial (NCT04720313) who were not exposed to prior BCMA-targeted therapy, producing a median progression free survival (mPFS) of 12.3 months
• 87% overall response rate (32 of 37 patients at the therapeutic dose of 800 million CAR+T cells) was observed in NEXICART-1 (NCT04720313) trial in relapsed/refractory multiple myeloma (including both patients with and without prior BCMA-targeted therapy) (Haematologica, 5^th European CAR-T cell meeting, 49^th EBMT meeting https://www.nexcella.com/publications/)
• 57% complete response rate (21 out of 37 patients at the therapeutic dose of 800 million CAR+T cells) (including both patients with and without prior BCMA-targeted therapy)
• The $13.9 billion Multiple Myeloma market in 2017 is expected to reach $28.7 billion in 2027 according to Wilcock, et al. Nature Reviews
• The expected primary endpoint for NXC-201 in relapsed/refractory multiple myeloma is overall response rate and duration of response
• Additionally, favorable NXC-201 safety data support investigating NXC-201 as the first potential outpatient CAR-T cell therapy, potentially reducing NXC-201 CAR-T-related hospitalization costs by up to 80%
• Nexcella plans to submit for FDA approval in multiple myeloma once 100 patients are treated with NXC-201

AL Amyloidosis

• 100% (8/8) overall response rate, 71% organ response rate (cardiac, renal, liver), 63% complete hematologic response rate (minimum residual disease negativity 10^-5), for NXC-201 in 8 relapsed/refractory AL Amyloidosis patients in our ongoing phase 1b/2a NEXICART-1 clinical trial (NCT04720313) (Clinical Cancer Research, 5^th European CAR-T cell meeting, 49^th EBMT meeting https://www.nexcella.com/publications/)
• The Amyloidosis market was $3.6 billion in 2017, expected to reach $6 billion in 2025, according to Grand View Research
• The expected primary endpoint for NXC-201 in relapsed/refractory AL Amyloidosis is overall response rate
• Nexcella plans to submit for FDA approval in AL amyloidosis once 30-40 patients are treated with NXC-201

“We continue on our path toward 100 patients treated with NXC-201 and a planned BLA submission to the FDA for approval of NXC-201,” said Gabriel Morris, President of Nexcella. “The waiting lists at major academic medical centers in the United States for multiple myeloma CAR-Ts reflect the potential demand for NXC-201.”

“95% of US medical centers cannot offer CAR-T today due to their severe side effect profile,” said Ilya Rachman, M.D., Executive Chairman of Nexcella. “Favorable NXC-201 tolerability could result in not only a 3-day hospital stay instead of the CAR-T standard 14-day hospital stay, but also enable NXC-201 to be delivered in the 95% of US medical centers that cannot offer CAR-Ts today, potentially reducing hospitalization costs by up to 80%.”

The 49^th EBMT poster can be accessed on the Nexcella corporate website at this link: https://www.nexcella.com/publications/

Poster Presentation:

Title: “Point-of-care CART manufacture and delivery for the treatment of multiple myeloma and AL amyloidosis: the experience of Hadassah Medical Center”

Event: European Society for Blood and Marrow Transplantation 49th Annual Meeting

Dates: April 23-26, 2023

Location: Palais des Congrès de Paris, 2 Pl. de la Prte Maillot, 75017 Paris, France

Times: Sunday, April 23 08:30 – 19:20 CEST / Monday, April 24 09:00 – 18:00 CEST / Tuesday, April 25 09:00 – 18:00 CEST / Wednesday, April 26 08:30 – 14:15 CEST

The Phase 1b portion of the ongoing Phase 1b/2 clinical trial has been successful in determining the recommended Phase 2 dose (RP2D) of 800 million CAR+T cells. Over the coming months, Nexcella plans to submit an IND application to the FDA for a Phase 1b/2 of NXC-201 in relapsed/refractory multiple myeloma and AL amyloidosis in order to expand the ongoing clinical to the U.S. The expected primary endpoint for the Phase 2 portion of the ongoing Phase 1b/2 clinical trial of NXC-201 in relapsed/refractory multiple myeloma is overall response rate and duration of response. Nexcella plans to submit data to the FDA in multiple myeloma once 100 patients are treated with NXC-201. The expected primary endpoint for NXC-201 in relapsed/refractory AL Amyloidosis is overall response rate. Nexcella plans to submit data to the FDA in AL amyloidosis once 30-40 patients are treated with NXC-201.

About NEXICART-1

NEXICART-1 (NCT04720313) is an ongoing Phase 1b/2, open-label study evaluating the safety and efficacy of NXC-201 (formerly HBI0101), in adults with relapsed or refractory multiple myeloma and AL amyloidosis.
The primary objective of the Phase 1b portion of the study, is to characterize the safety and confirm the Maximally Tolerated Dose (MTD) and Phase 2 dose of NXC-201. The Phase 2 portion of the study will evaluate the efficacy and safety of NXC-201 with endpoints of overall survival, progression-free survival and response rates according to International Myeloma Working Group (IMWG) Uniform Response Criteria.

About NXC-201

NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.

About Multiple Myeloma

Multiple myeloma (“MM”) is an incurable blood cancer of plasma cells that starts in the bone marrow and is characterized by an excessive proliferation of these cells. Despite initial remission, unfortunately, most patients are likely to relapse. There are 35,730 patients in the United States diagnosed with MM each year. Prognosis for patients who do not respond to or relapse after treatment with standard therapies, including protease inhibitors and immunomodulatory agents remains poor.

About AL Amyloydosis

AL amyloidosis is a rare systemic disorder caused by an abnormality of plasma cells in the bone marrow. Misfolded amyloid proteins produced by plasma cells cause buildup in and around tissues, nerves and organs, gradually affecting their function. This can cause progressive and widespread organ damage, and high mortality rates.

AL amyloidosis affects roughly 30,000 – 40,000 patients in total throughout the U.S. and Europe, and it is estimated that there are approximately 3,000 – 4,000 new cases of AL amyloidosis annually in the U.S. The annual global incidence of AL Amyloidosis is ~15,000 patients. 

About Nexcella, Inc.

Nexcella, Inc., a 98%-owned subsidiary of Immix Biopharma, Inc (NASDAQ:IMMX), is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our N-GENIUS platform allows us to discover, develop, and manufacture cutting-edge cell therapies for patients in need. To learn more about Nexcella, Inc. visit us at www.nexcella.com.

About Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio^TM) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)^TM targeting oncology and immuno-dysregulated diseases. Our lead asset is IMX-110, currently in Phase 1b/2a clinical trials as a monotherapy and in its IMMINENT-01 combination clinical trial with BeiGene/Novartis’ anti-PD-1, tisleilizumab, for which patient dosing begin in Feb 2023. IMX-110 holds orphan drug designation (ODD) by the FDA for soft tissue sarcoma, and has received Rare Pediatric Disease Designation (RPDD) by the FDA the treatment of rhabdomyosarcoma, a life-threatening form of cancer in children. RPDD qualifies ImmixBio to receive fast track review and a priority review voucher (PRV) at the time of marketing approval of IMX-110. Additionally, ImmixBio owns 98% of Nexcella, Inc, developing CAR-T NXC-201 for multiple myeloma and AL amyloidosis, with 92% and 100% response rates in each indication, respectively, as of February 9, 2023. Learn more at www.immixbio.com.

Forward Looking Statements

This press release contains “forward-looking statements” Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Immix Biopharma’s Annual Report on Form 10-K for the year ended December 31, 2022, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Immix Biopharma, Inc. specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements.

Investor Contact:

Suzanne Messere
Stern Investor Relations
[email protected]

Company Contact:


[email protected]

Attachment

• Nexcella Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris